Emiliem, Inc. Press Release - January 12, 2007

Emiliem, Inc. and MIR Preclinical Services sign cancer pharmacology agreement.

Emiliem, Inc. and MIR Preclinical Services (MIR) announce the signing of an agreement whereby MIR will conduct broad preclinical services for Emiliem on its multi-kinase inhibitors created through its K-STAR technology. The agreement includes preclinical oncology assessments and evaluations of Emiliem’s novel anti-tumor agents using xenograft, orthotopic and transgenic animal models. Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem, stated “We are extremely pleased to form this relationship with MIR whose expertise and technologies will be instrumental for our quest to create innovative clinical drug development candidates. MIR employs a wide array of novel imaging technologies in its preclinical models to measure response to therapy at anatomical, functional and molecular levels. Many of these imaging technologies can be translated into clinical benchmarks which will eventually speed our evaluation of therapeutic response in cancer patients.”

“We are eager to apply our technologies and drug discovery experience to the development of Emiliem’s novel compounds”, stated Dr. W. R. Leopold, President and CEO of MIR Preclinical Services. “We especially enjoy working closely with our clients, as an extension of their drug discovery effort. We look forward to working with Emiliem to select and characterize novel drug candidates for clinical trials.”

About Emiliem

Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The Company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates.
The Company is headquartered in Emeryville, California.

This document is intended to provide information regarding initiatives of Emiliem, Inc. It is not intended as a general advertisement nor an offer to sell or a solicitation of an offer to buy any securities or an interest in Emiliem, Inc. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information, matters described are forward-looking statements that involve risks and uncertainties, including: dependence on third parties for testing, development, regulatory approval, and successful commercialization of products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical development efforts, and other similar risks. Actual results may differ materially from those projected. These forward-looking statements are made only as of the date of release of this document, and the company disclaims any intent or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	Emiliem, Inc. Press Release - January 12, 2007 Emiliem, Inc. and MIR Preclinical Services sign cancer pharmacology agreement. Emiliem, Inc. and MIR Preclinical Services (MIR) announce the signing of an agreement whereby MIR will conduct broad preclinical services for Emiliem on its multi-kinase inhibitors created through its K-STAR technology. The agreement includes preclinical oncology assessments and evaluations of Emiliem’s novel anti-tumor agents using xenograft, orthotopic and transgenic animal models. Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem, stated “We are extremely pleased to form this relationship with MIR whose expertise and technologies will be instrumental for our quest to create innovative clinical drug development candidates. MIR employs a wide array of novel imaging technologies in its preclinical models to measure response to therapy at anatomical, functional and molecular levels. Many of these imaging technologies can be translated into clinical benchmarks which will eventually speed our evaluation of therapeutic response in cancer patients.” “We are eager to apply our technologies and drug discovery experience to the development of Emiliem’s novel compounds”, stated Dr. W. R. Leopold, President and CEO of MIR Preclinical Services. “We especially enjoy working closely with our clients, as an extension of their drug discovery effort. We look forward to working with Emiliem to select and characterize novel drug candidates for clinical trials.” About Emiliem Emiliem, Inc. is a developmental-stage biotechnology company focused on the discovery and development of molecularly targeted oncology drugs. The Company has developed proprietary drug design technologies that facilitate the inclusion of multiple kinase inhibitor profiles into single compounds. Emiliem's approach to developing targeted drugs includes the ability to identify proprietary biomarkers. Coupling drug discovery with biomarker identification and implementation increases the likelihood of achieving clinical trial endpoints and receiving approval to market these innovative drug candidates. The Company is headquartered in Emeryville, California. This document is intended to provide information regarding initiatives of Emiliem, Inc. It is not intended as a general advertisement nor an offer to sell or a solicitation of an offer to buy any securities or an interest in Emiliem, Inc. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information, matters described are forward-looking statements that involve risks and uncertainties, including: dependence on third parties for testing, development, regulatory approval, and successful commercialization of products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical development efforts, and other similar risks. Actual results may differ materially from those projected. These forward-looking statements are made only as of the date of release of this document, and the company disclaims any intent or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.